<DOC>
	<DOCNO>NCT00633919</DOCNO>
	<brief_summary>This trial design evaluate efficacy specific immunotherapy SLITone Dermatophagoides mix compare placebo subject house dust mite allergic asthma , base asthma medication use period 2 month high environmental exposure mite ( autumn 2008 ) .</brief_summary>
	<brief_title>Efficacy SLITone House Dust Mite Allergic Patients</brief_title>
	<detailed_description>This trial conduct multi-centre , randomise , double-blind , parallel-group , placebo-controlled phase III trial , assess efficacy SLITone Dermatophagoides mix adult ( 18-65 year ) . 5 centre Spain participate . Subjects house dust mite allergic asthma randomise receive either SLITone Dermatophagoides mix ( active ) placebo treatment ( 1:1 ) approximately 1 year . The trial duration extend 2 year . Administration do sublingually ( tongue ) daily preferably morning . A monodose container comprise daily dose 200 STU . Subjects keep asthma control entire trial ( 2 year ) . Except 2 evaluation period 2 month autumn 2007 autumn 2008 , subject use medication prescribed physician . During 2 evaluation period 2 month autumn 2007 autumn 2008 , subject use provide standardised rhinoconjunctivitis asthma medication . The asthma medication use reflect subject 's asthma status . This do treatment low maintenance dose control medication supplement rescue medication need . Rhinoconjunctivitis medication 2 evaluation period autumn 2007 autumn 2008 ; standardise medication use relieve rhinoconjunctivitis symptom , subject provide follow free medication need : - Desloratadine tablet ( 5 mg per tablet ; anti-histamine ; Aerus® ) - Budesonide nasal spray ( 64 µg per puff ; inhale corticosteroid ) - Prednisone tablet ( 5 mg per tablet ; oral corticosteroid ) Subjects instruct use medication instead usual medication 2 evaluation period autumn 2007 autumn 2008 , record use medication symptom daily diary . Asthma medication evaluation period autumn 2007 ; prior 2 month evaluation period autumn 2007 , asthma control medication use interrupt obtain medication-free period . Subjects provide follow free medication standardise treatment use relieve asthma symptom : - Salbutamol inhaler ( 200 µg per puff ; short act β2-agonist ; Ventilastin® ) . - Budesonide/formoterol inhaler ( 80/4.5 µg per inhalation ; combination inhale corticosteroid long acting β2-agonist ; Symbicort® ) . - Prednisone tablet ( 5 mg per tablet ; oral corticosteroid ) . Subjects instruct use medication instead usual medication evaluation period autumn 2007 follow : They use salbutamol inhaler asthma rescue medication either : - need 4 inhalation salbutamol per day 2 consecutive day - suffer nocturnal asthma force wake - suffer exercise-induced dyspnoea ordinary task In case , subject contact investigator determine amount budesonide/formoterol use daily asthma control medication . The budesonide/formoterol inhaler thereafter use rescue medication need instead salbutamol . Prednisone could use last option . Asthma medication evaluation period autumn 2008 : At 2 month evaluation period autumn 2008 , subject maintain low dose budesonide/formoterol ( daily asthma control medication ) use budesonide/formoterol inhaler rescue medication need . Prednisone could use last option . Asthma medication use evaluation period autumn 2007 autumn 2008 record daily diary . One primary efficacy endpoint 16 secondary efficacy endpoint assess ; result primary efficacy endpoint , 3 secondary endpoint adverse event reporting post . None secondary endpoint demonstrate difference treatment group .</detailed_description>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<criteria>A clinical history house dust mite induce persistent mild moderate . asthma , without concurrent rhinoconjunctivitis , least 1 year evolution . Demonstration positive specific serum IgE test Dermatophagoides year prior screen visit ( CAP Class 2 high equivalent ) . Positive Skin Prick Test response ( wheal diameter ≥ 3 mm ) Dermatophagoides mix . If premenopausal female childbearing potential , subject must test negative standard urine pregnancy test . Willingness comply protocol . FEV1 &lt; 70 % predict value appropriate medication . Asthma control randomization without need inhale corticosteroid dose high 1000 µg/day beclometasone equivalent . A clinical history symptomatic perennial allergic asthma cause allergens subject regularly expose ( Alternaria , cat ) , house dust mite . Chronic sinusitis . Aspirin sulfite intolerance . Chronic obstructive pulmonary disease . Current severe atopic dermatitis . Severe asthma . Use investigational drug within 30 day prior screen . Previous immunotherapy house dust mite allergens least 2 year within previous 10 year . At randomisation , current symptom , treatment , upper respiratory tract infection , acute sinusitis , acute otitis medium relevant infectious process ( serous otitis medium exclusion criterion ) . Physical examination clinically relevant finding . Any following underlying condition know suspected present : Cystic fibrosis , malignancy , insulindependent diabetes , malabsorption malnutrition , renal hepatic insufficiency , chronic infection , drug dependency alcoholism , ischaemic heart disease angina require current daily medication evidence disease make implementation protocol interpretation protocol result difficult jeopardise safety subject ( e.g . clinically significant cardiovascular , serious immunopathologic , immunodeficiency whether acquire , hepatic , neurologic , psychiatric , endocrine , major systemic disease ) . Immunosuppressive treatment . A mental condition render subject unable understand nature , scope possible consequence trial , and/or evidence uncooperative attitude . Unlikely able complete trial . Unwillingness comply trial protocol regimen asthma and/or rhinoconjunctivitis medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>House dust mite</keyword>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Allergy</keyword>
	<keyword>Allergic asthma</keyword>
</DOC>